# A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex

> **NCT00000710** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00000710
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1990-05
- **Target enrollment:** 42 (—)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000710, "A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*